Your browser doesn't support javascript.
loading
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
Bourmaud, Aurélie; Henin, Emilie; Tinquaut, Fabien; Regnier, Véronique; Hamant, Chloé; Colomban, Olivier; You, Benoit; Ranchon, Florence; Guitton, Jérôme; Girard, Pascal; Freyer, Gilles; Tod, Michel; Rioufol, Catherine; Trillet-Lenoir, Véronique; Chauvin, Franck.
Affiliation
  • Bourmaud A; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. aurelie.bourmaud@icloire.fr.
  • Henin E; Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France. aurelie.bourmaud@icloire.fr.
  • Tinquaut F; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. emilie.henin@univ-lyon1.fr.
  • Regnier V; Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France. Fabien.tinquaut@icloire.fr.
  • Hamant C; Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France. Veronique.regnier@icloire.fr.
  • Colomban O; Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France. chloe.hamant@free.fr.
  • You B; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. olivier.colomban@univ-lyon1.fr.
  • Ranchon F; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. benoit.you@chu-lyon.fr.
  • Guitton J; Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France. benoit.you@chu-lyon.fr.
  • Girard P; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. florence.ranchon@chu-lyon.fr.
  • Freyer G; Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France. florence.ranchon@chu-lyon.fr.
  • Tod M; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. jerome.guitton@chu-lyon.fr.
  • Rioufol C; Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France. jerome.guitton@chu-lyon.fr.
  • Trillet-Lenoir V; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. pascal.girard@merckgroup.com.
  • Chauvin F; EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France. gilles.freyer@chu-lyon.fr.
BMC Res Notes ; 8: 291, 2015 Jul 04.
Article in En | MEDLINE | ID: mdl-26142140
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Colorectal Neoplasms / Medication Adherence / Capecitabine / Antimetabolites, Antineoplastic Type of study: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Res Notes Year: 2015 Document type: Article Affiliation country: France Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Colorectal Neoplasms / Medication Adherence / Capecitabine / Antimetabolites, Antineoplastic Type of study: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: BMC Res Notes Year: 2015 Document type: Article Affiliation country: France Country of publication: United kingdom